Eli Lilly (NYSE: LLY) doesn't really need much of an introduction.
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Shares of Eli Lilly and Company  LLY are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected.
Weight-loss medications have exploded in popularity but the health-benefits go beyond obesity.

Eli Lilly: Market Overreacted

05:38am, Tuesday, 21'st Jan 2025
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction, LLY still pr
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (LLY -4.21%). At one point, share prices had gained as much as 65% on the year.
In the first half of 2024, it seemed Eli Lilly (LLY -4.21%) could do no wrong. Unfortunately, the good times didn't last very long.

3 Unstoppable Stocks to Buy in 2025

06:40am, Saturday, 18'th Jan 2025
You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recentl
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Being a long-term investor brings a unique peace of mind. It requires thinking in decades, not months or years, which allows an investor to focus on owning exceptional businesses.
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one poi
VALLEY STREAM, NY — The FDA announced the approval last month of the first drug for patients suffering from obstructive sleep apnea. "This medicine is just another in our arsenal of tools that we ca
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE